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Background: Diastolic dysfunction is seen in the majority of patients with hypertrophic cardiomyopathy (HCM) and is recognized as 
an important contributor to symptoms and a predictor of adverse outcomes. No medical treatment has yet been reliably shown to halt 
or reverse disease progression but pilot studies of angiotensin receptor blockers have suggested an effect on diastolic function and 
symptomatic burden. We assessed the effects of losartan on diastolic function, symptoms, exercise capacity and NT-pro-BNP compared to 
placebo.
methods:  In a randomized, double-blind design 133 patients with HCM (52±13 years, 35% female) were assigned to losartan (100 mg/d) 
or placebo for 12 months. Endpoints were changes in left atrial volume as assessed by cardiac magnetic resonance imaging or cardiac 
computed tomography, diastolic function assessed by Doppler echocardiography, exercise capacity, NYHA-class and NT-pro-BNP.
results: At follow-up left atrial volume had increased significantly in both groups (placebo from 68±25 to 75±27 ml/m2, p<0.001 and 
losartan from 63±22 to 68±26 ml/m2, p=0.017). However, the increase did not differ significantly between groups (mean difference 2 ml/
m2, [95% CI, -4 to 8 ml/m2], p=0.50). E/A, E/e’ and early deceleration time were unchanged from baseline to follow-up and did not differ 
between groups. Estimated peak VO2 remained unchanged (placebo 25±10 to 26±10 ml/min/kg and losartan 27±8 to 27±8 ml/min/kg) and 
did not differ between groups (p=0.08). There was no significant difference in changes in NYHA class between the two groups (p=0.61). 
A small increase was seen in NT-pro-BNP concentration in both groups (placebo 22 [9-47] to 24 [14-53] pmol/l, p<0.05 and losartan 17 
[10-48] to 26 [15-59] pmol/l, p=0.01). However, the increase did not differ between groups (placebo 3 [-6-18] pmol/l and losartan 4 [-1-
15] pmol/l, p=0.67). Losartan was generally well tolerated without increase in left ventricular outflow tract gradients or haemodynamic 
compromise.
conclusion:  In patients with overt HCM, losartan had no effect on diastolic parameters, dyspnea, exercise capacity or NT-pro-BNP 
compared to placebo.
